TP53 and cancer: This and the observations that replicative age is also an independent poor prognostic factor when assessed in cancer tissue and that mifepristone, reduces the number of TP53 mutant clones, strongly supports the view that the antiprogestins mifepristone and ulipristal acetate are attractive cancer-preventive candidates in young women.